InsiderSignal.AI

InsiderSignal.ai

SGP - Spyglass Pharma, Inc.

Insider Purchase by Mathers Edward T (10%)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Mathers Edward T, serving as 10% owner at Spyglass Pharma, Inc. (SGP), purchased 937,500 shares at $16.00 per share, for a total transaction value of $15,000,000.00. Following this transaction, Mathers Edward T now holds 6,035,038 shares of SGP.

This purchase represents a 18.00% increase in Mathers Edward T's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, February 9, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, February 11, 2026, 2 days after the trade was made.

Mathers Edward T

10%

Edward T. Mathers is a prominent venture capital investor and manager who serves as a key decision-maker at New Enterprise Associates 17, L.P. (NEA 17), one of the leading venture capital firms[[1]](https://www.stocktitan.net/sec-filings/SGP/form-3-spy-glass-pharma-inc-initial-statement-of-beneficial-ownership-0cb8675a6e1d.html)[[2]](https://www.stocktitan.net/sec-filings/SGP/form-4-spy-glass-pharma-inc-insider-trading-activity-ff537c6f6bac.html). Through his role as a manager of NEA 17 GP, LLC, the general partner of NEA 17, Mathers holds a 10% beneficial ownership stake in SpyGlass Pharma, Inc. (SGP)[[1]](https://www.stocktitan.net/sec-filings/SGP/form-3-spy-glass-pharma-inc-initial-statement-of-beneficial-ownership-0cb8675a6e1d.html)[[2]](https://www.stocktitan.net/sec-filings/SGP/form-4-spy-glass-pharma-inc-insider-trading-activity-ff537c6f6bac.html). His investment portfolio through NEA 17 demonstrates significant confidence in emerging pharmaceutical ventures, with his entity's holdings in SpyGlass including substantial positions in multiple preferred stock series that converted to common stock ahead of the company's initial public offering in February 2026[[1]](https://www.stocktitan.net/sec-filings/SGP/form-3-spy-glass-pharma-inc-initial-statement-of-beneficial-ownership-0cb8675a6e1d.html)[[2]](https://www.stocktitan.net/sec-filings/SGP/form-4-spy-glass-pharma-inc-insider-trading-activity-ff537c6f6bac.html). Mathers' involvement with SpyGlass Pharma reflects his strategic investment activity in the biopharmaceutical sector[[2]](https://www.stocktitan.net/sec-filings/SGP/form-4-spy-glass-pharma-inc-insider-trading-activity-ff537c6f6bac.html). On February 9, 2026, concurrent with SpyGlass's IPO, NEA 17 converted preferred stock holdings totaling 5,097,538 shares into common stock and subsequently purchased an additional 937,500 common shares at $16 per share, bringing the entity's total common stock position to 6,035,038 shares[[2]](https://www.stocktitan.net/sec-filings/SGP/form-4-spy-glass-pharma-inc-insider-trading-activity-ff537c6f6bac.html). This substantial investment underscores Mathers' active role in identifying and supporting promising pharmaceutical companies in their growth and public market transition stages[[2]](https://www.stocktitan.net/sec-filings/SGP/form-4-spy-glass-pharma-inc-insider-trading-activity-ff537c6f6bac.html).

View full insider profile →

Trade Price

$16.00

Quantity

937,500

Total Value

$15,000,000.00

Shares Owned

6,035,038

Trade Date

Monday, February 9, 2026

13 days ago

SEC Filing Date

Wednesday, February 11, 2026

Filed 2 days after trade

About Spyglass Pharma, Inc.

Company Overview

No company information available
View news mentioning SGP

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3898261

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime